Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am only looking at PLSE. Haven't looked at MYOK and that one sounds interesting so I may check it out but there already is Entresto from NVS. I am familiar with the ISRG/CM history since I had isrg and watched the struggle. Duggan has done well with that starting stake. PLSE is a still very much a science company.
PLSE - Truly amazing run given the FDA issues. 10Q has section and comments about FDA risk but not much more offered on what soft tissue data the FDA asked for that caused prior management to withdrawal application. Duggan has replaced completely the prior management since. He now owns 36% of company. Is that the only reason the stock has rocketed from his $15 purchase price? Low float and illiquid options makes this highly volatile but I may give it a shot.
http://services.corporate-ir.net/SEC.Enhanced/SecCapsule.aspx?c=254359&fid=15283322
TRXC - From CC yesterday. 3mm "micro or scarless" lap instruments to be released in EU in 1H 2018 then articulating instruments also first in EU to be followed by US after FDA clearance. No time line given for submittals. It will be interesting to see how well the instruments do in the EU. I thought articulation maybe tricky to implement with haptics and conventional Lap movement. Apparently not.
On financing front, they wasted no time gathering $$ using their ATM and completed it in October. $100M of cash now on the books should be ample if early interest turns into sales. Sales cycle is 4-6 quarters as with other large cap hospital equipment. Some early adopters have placed or close to placing orders, Taiwan (q3) prior to clearance), EU and US. One each in latter regions.
IMO prior comforting words from CEO that they have no intention of going head to head with ISRG should not be very comforting at all to ISRG particularly with regards to release of articulating tools.
LOL. Oh Sport you try hard. FDA clearance was in Q4. I guess the Taiwan surgeons were optimistic about clearance to install one even before then and with no Taiwan clearance. Tells you a little bit about demand now that clearance in the biggest market is official.
3mm and articulating instruments to be released in EU next year followed by USA. Seems 3mm devices will limit prospects for single port.
ATM was done in Oct. Cash on hand now $100M. o/s at 199M. Taking series B warrants into acct, around 220M o/s. Financing risk is now minimal.
Directly stolen from offshore O&G industry with a lot fewer parts and easier installation.
https://energy.gov/eere/wind/articles/offshore-floating-vertical-axis-wind-turbine-project-identifies-promising
How did you arrive at the starting point of 173.5M shrs before series A exercise?
Series a warrants 24.9M. Series b warrants 18.7M. Total of 43.6M if o/s doesn't include warrants. Back to my original est of ~220M shrs including ATM if so.
Just looked at the PR and the Q3 slides. Mentioned work on automation ahead of guidance. I was not aware of guidance. What was the guidance?
Would appreciate link if you have seen it.
Current o/s count includes series a and b warrants. I didn't take that into acct in my prior review of share structure. Additional shrs will depend on prices received on sales of ATM shares. There is $50M ATM outstanding if recollection serves. Assuming a conservative $2/shr would add 25m shrs. So 170M+ shrs o/s compared to my prior estimate of ~220M shrs prior to fda clearance.
RE AZN and other bios in China. Any idea whether China controls GM of medicines? My experience from long ago was that they would target an acceptable ROR for a foreign company operating in THEIR country, and things like taxes, profit share, etc ... get adjusted periodically. For drugs, I think they could set the price and adjust it down as sales goes up. That is if they still have the same policies as 20 yrs ago.
Glad it was minor. AP said truck backed into shuttle that was stopped. Truck driver was cited for backing up illegally.
http://www.sfgate.com/news/article/Driverless-shuttle-bus-crashes-after-launch-in-12342316.php#photo-14515506
Cognitive dissonance or unrealistic expectations? My position was called away in the mid 30's months ago. Nuplazid sales looks ok.
The new Nissan Leaf looks like a winner. It may be a good way to go for those not wanting to wait for the 3.
https://insideevs.com/nissan-leaf-sales-japan-october-2017/
Waymo first out of the gate. I have seen the vans in Mountain View always with someone in driver's seat. MIT Tech Review has article on Uber effort in Pittsburgh and it is not ready for prime time.
https://www.bloomberg.com/news/articles/2017-11-07/waymo-driverless-cars-are-now-driverless-in-ground-breaking-test
Minor. Only 40 options @0.03. I am guessing is a bullish vertical spread. 5 and 8 strikes for net 2 cents. An ~$90 bet after commissions. The 2000 $5 options is the much more serious bet.
Easy solution. Then cancel the reservation and buy something other EV and be relieved of all your anguish. Or maybe it is all shorting BS anyway. I have a small amount of puts that will expire worthless soon. I hope Musk succeeds and I am sure I will be one of his customers in the future.
Forbes is becoming a magazine that belongs next to the toilet when authors don't think through implications of legislation for specific companies. Tesla is very close to the sales limit when the $7500 federal credit no longer applies. Elimination of the credit will hurt all EV makers but it will only have a tiny effect on tesla. It is also a small issue for most S and X buyers.
2000 Nov 17 $5 options bought at 0.05 by someone this morning. We shall find out whether it is a good $10k wager in a few days.
I believe that has been true for the Da Vinci since the beginning. The marketing of the Da Vinci to the early hospitals was that it brought in more surgical patients, most of whom were not appropriate for robotics, but more than made up the loss leader from other services rendered. The major push came from prostate surgery and the claim that there is a better chance of preserving potency and patients wanted hospitals that have the robots. There is some cost savings to be had from faster recovery and shorter hospital stays. The jury is still out on TRXC as their Senhance has much lower procedural cost and should help lap surgeons become less fatigued and use lap techniques/motions that they are already trained to do. Whereas Da Vinci is more for adoption for open surgery to MIS. That's why the vast majority of lap surgeries still have not been penetrated by Da Vinci. That's my understanding of how TRXC is portraying their edge. Whether they actually sell substantial systems to lap surgeons based upon that edge is the question.
trxc - In IRAs bought back half a position in shares and sold half position of in the money puts. Will trade to lower cost basis as opp presents. Rick Wise of Stifel has PT guess of 3.75.
clsn - 800K in fees on $6.6M raise. Why bother?
trxc - scaling back in at a leisurely pace on this correction back to prices at day following 510K clearance. Probably at half the amount of shares that I had before selling out as I still have shares in taxable account.
Link?
CEO still holds 3.6M shares plus options after his option exercise and sale of 600K shrs. He is allowed to manage his risk. More telling is the CFO holding on to most of his shares from his exercise 200K warrants. CFO's are typically risk adverse.
RDS - buying of EV charging stations in EU. Although I am not sure whether colocating EV charging with gasoline stations is a good idea.
https://chargedevs.com/newswire/shell-acquires-dutch-charging-network-newmotion/
thx. I find it curious that the FDA cleared the MR system (Perspectum) for early liver disease imaging with minimal biopsy supporting data. That's the implication because the trial to collect biopsy data to support imaging results is not to be completed for another 3 years. There had to be some biopsy data?
https://clinicaltrials.gov/ct2/show/NCT03165201
wrt FXR valuation, ICPT had peaked close to 6.7B EV as of May 2015 10Q compared to the current ~1.5B. What should it be for something that works and where do you place enta's probability of success?
Cash flies fast at Titan Medical. Just look at the frequency of their transactions from Bloom Burton's page. ISRG already has had their single port (DaVinci SP) cleared and ready to go for a while.
https://www.bloomburton.com/transactions/
trxc - CEO exercised 0.35 options sells 600K shares at average of 3.68 He still has 3.6M shares + options. I haven't bought back any shares yet in my IRAs.
What's your low estimate guess on where market share will end up at compared to market (via enta sp) expectations? I know it is approximate but give it a shot.
Is the company contemplating that? I was at a super charger location 2 days ago and I saw only 2 stalls being used and there were at least 10 stalls there. I imagine it is busier on a weekend. If they do that, I think they need to very careful about priority and pissing off Tesla owners.
Right on the top of the great Kelly-Snyder oil field aka SACROC in west Texas. It is so windy there that the only thing growing on the ground is mesquite.
http://nawindpower.com/amazon-wind-farm-texas-now-operational-scurry-county
I use the stairs or a foam roller. Friend's instruction was to hold the stretch for 90 secs. 4X per day. The cheapo scholl's orthotics has noticeably reduced foot fatigue post exercise. Still need good shoes to go with those. New Balance I find superior.
Stretching and orthotics did the trick for me after my first episode. I didn't have to go with customise orthotics, just dr scholls at local pharmacy. My podiatrist friend told me what to do. I was too lazy in stretching before and after exercising. I also talked with him about rvnc's trial. Nothing new there according to him. It is being done already in many practices depending on patient preferences and willingness to pay out of pocket for botox. Wasn't expensive if recollection serves in comparison to custom orthotics.
How big of a cohort is required to validate (or not) these N=1, (these referring to complete molecular remission seen earlier) observations? So far these have not budged market skepticism that seems on wanting to see magical results.
closed out IRA long positions at 4.9+ on average. Too crazy. Hedged non IRA shares with calls.
trxc - From the CC this morning, Rick Wise of Stifel sounded surprised at the two indications applied for and cleared. GYN and colorectal are large and more complex indications so it suggest company will have an easy road ahead in expanding to other indications. CEO doesn't plan to go head to head with ISRG on accounts although some current EU installations are ISRG users. They plan to go after existing LAP procedures (ISRG goes after conversion of open to robotics) that are not using ISRG, probably because of cost vs reimbursement issues. I think any administrator will look at Senhance if they are going through a replacement cycle as economics is just better. Note on Rick Wise, he was on the ISRG story when they were still beta testing. I am not sure what fair value at this stage is given the lack of sales data. I was guessing 1B market cap for now but Wise's Q&A suggest I am too conservative longer term.
Sheesh, market cap is already pushing 900M as I was typing this. What a rocket.
Correct about the series A warrants. A director also exercised 250K warrants and held on to shares.